Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity
Rania Dagher, Varsha Kumar, Alan M. Copenhaver, et al.
European Respiratory Journal (2021) Vol. 59, Iss. 3, pp. 2004306-2004306
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy
Hiroyuki Nagase, Maho Suzukawa, Keiji Oishi, et al.
Allergology International (2022) Vol. 72, Iss. 1, pp. 11-23
Open Access | Times Cited: 62
Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight
Imran Howell, Aleksandra Howell, Ian Pavord
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 7
Open Access | Times Cited: 26
Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study
Alicia Padilla, Isabel Carmona, Pilar Ausín, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 22
Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways
Alexander Eggel, Luke F. Pennington, Theodore S. Jardetzky
Immunological Reviews (2024)
Open Access | Times Cited: 10
Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis
Alexandra Nanzer, Anne-Catherine Maynard-Paquette, Vardah Alam, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 3, pp. 724-732
Closed Access | Times Cited: 9
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
Laura Pini, Diego Bagnasco, Bianca Beghè, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 3013-3013
Open Access | Times Cited: 9
Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
Raffaele Campisi, Santi Nolasco, Corrado Pelaia, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 12, pp. 3953-3953
Open Access | Times Cited: 21
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Alessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 20
Natural killer cells in the lung: potential role in asthma and virus-induced exacerbation?
Florian Leprêtre, Delphine Gras, Pascal Chanez, et al.
European Respiratory Review (2023) Vol. 32, Iss. 169, pp. 230036-230036
Open Access | Times Cited: 17
Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients
Laura Bergantini, Miriana d’Alessandro, Tommaso Pianigiani, et al.
Clinical Immunology (2023) Vol. 253, pp. 109680-109680
Open Access | Times Cited: 13
Clinical remission in severe asthma: lights and shadows on an ambitious goal
Corrado Pelaia, Eleonora Zannoni, Giovanni Paoletti, et al.
Current Opinion in Allergy and Clinical Immunology (2024) Vol. 24, Iss. 4, pp. 230-236
Closed Access | Times Cited: 5
Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
Yasuhiko Koga, Haruka Aoki‐Saito, Yosuke Kamide, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma
Michael Fricker, John Harrington, Sarah A. Hiles, et al.
Allergy (2024) Vol. 79, Iss. 11, pp. 3118-3128
Open Access | Times Cited: 4
Endotyping in Chronic Rhinosinusitis—An EAACI Task Force Report
Sanna Toppila‐Salmi, Sietze Reitsma, Valérie Hox, et al.
Allergy (2024) Vol. 80, Iss. 1, pp. 132-147
Closed Access | Times Cited: 4
Emerging biological treatments for asthma
Daniela Pastore, Chiara Lupia, Maria D’Amato, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries From Central Eastern Europe and Baltics
Florin Mihălţan, Zsuzsanna Csoma, Norbert Pauk, et al.
Journal of Asthma and Allergy (2025) Vol. Volume 18, pp. 195-210
Open Access
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study
Luisa Brussino, Maria Aliani, Elena Altieri, et al.
Frontiers in Allergy (2025) Vol. 6
Open Access
Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies
Mayu Shiomi, Ryu Watanabe, Ryuhei Ishihara, et al.
Biomolecules (2025) Vol. 15, Iss. 4, pp. 544-544
Open Access
Eosinophilic Patterns in Patients with Seasonal Allergy Affected by Bronchial Asthma and Rhinitis/Rhinosinusitis: Efficacy of Benralizumab in Patients with the Persistent Pattern
Valentina D’Aiuto, Ilaria Mormile, Francescopaolo Granata, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 754-754
Open Access | Times Cited: 3
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
Laura Pini, Diego Bagnasco, Bianca Beghè, et al.
(2024)
Open Access | Times Cited: 3
Helper T cell subsets: Development, function and clinical role in hypersensitivity reactions in the modern perspective
Andy Ka Chun Kan, Wang Tik Tang, Philip H. Li
Heliyon (2024) Vol. 10, Iss. 9, pp. e30553-e30553
Open Access | Times Cited: 3
Viral infections causing asthma exacerbations in the age of biologics and the COVID-19 pandemic
Pedro A. Lamothe, Violeta Capric, F. Eun‐Hyung Lee
Current Opinion in Pulmonary Medicine (2024) Vol. 30, Iss. 3, pp. 287-293
Open Access | Times Cited: 2
Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events
Limor Rubin, Aviv Talmon, Yaarit Ribak, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 10, pp. e009658-e009658
Open Access | Times Cited: 2
Case Report: Eosinophilic Bronchiolitis With Eosinophil ETosis in Mucus Plugs Successfully Treated With Benralizumab
Hisashi Sasaki, Jun Miyata, Akiko Irie, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 11
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
Paolo Cameli, Maria Aliani, Elena Altieri, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 273-290
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top